Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$3.36 ▲ +0.01
(+0.30%)
MKT CAP: $333.1M • VOL: 911.2K
52W L $2 52W H $5
XFOR // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $35.1M | $2.6M | $0 |
| YoY Revenue Growth % | +1273.2% | — | — |
| Gross Profit | $29.4M | $1.8M | — |
| Gross Margin % | 83.6% | 68.8% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$86.9M | -$36.4M | -$107.5M |
| Operating Margin % | -80.0% | -80.0% | — |
| Net Income (GAAP) | -$79.2M | -$37.5M | -$101.2M |
| EBITDA (Normalized) | — | -$36.1M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$85.6M | -$130.9M | -$96.5M |
| Capital Expenditures (CapEx) | — | $326.0K | — |
| Free Cash Flow (FCF) | -$85.6M | -$131.2M | -$96.5M |
| FCF Margin % | -80.0% | -80.0% | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $217.0M | $55.7M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $186.3M | $22.1M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR XFOR.